BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
See today's BioWorld
Home
» Affimed shares sink on SAEs, clinical hold in AFM-11 phase I
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Affimed shares sink on SAEs, clinical hold in AFM-11 phase I
Oct. 10, 2018
By
Marie Powers
No Comments
On its second-quarter earnings call, Affimed NV promised much-anticipated clinical and abstract data updates in the fourth quarter on several pipeline programs, including AFM-11, its CD19/CD3-targeting T-cell engager.
BioWorld